Editor's Choice
Open Access
Review
Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy
Development of drug resistance represents the major cause of cancer therapy failure, determines disease progression and results in poor prognosis for cancer patients. Different mechanisms are responsible for drug resistance. Intrinsic genetic modifications of cancer cells induce the alteration......
This article belongs to the Special Issue Application of Liquid Biopsy for Prognostic Status of Cancers and Drug Response
Cancer Drug Resist 2020;3:356-370.
DOI: 10.20517/cdr.2020.04
Published on: 21 Mar 2020
Viewed: 1463 Downloaded: 317
Open Access
Review
PHGDH as a mechanism for resistance in metabolically-driven cancers
At the forefront of cancer research is the rapidly evolving understanding of metabolic reprogramming within cancer cells. The expeditious adaptation to metabolic inhibition allows cells to evolve and acquire resistance to targeted treatments, which makes therapeutic exploitation complex but......
This article belongs to the Special Issue Interrogating the Role of Metabolism in Acquired Drug Resistance
Cancer Drug Resist 2020;3:[Online First].
DOI: 10.20517/cdr.2020.46
Published on: 17 Sep 2020
Viewed: 264 Downloaded: 66
Open Access
Editorial
Cancer drug resistance: a new perspective
Cancer drug resistance has been and unfortunately still is a major problem in cancer therapy. Almost any therapy (except surgery) that is being used in the treatment of cancer can result in resistance. Unfortunately there is a large group of patients that will either not respond to the applied......
Cancer Drug Resist 2018;1:1-5.
DOI: 10.20517/cdr.2018.03
Published on: 19 Mar 2018
Viewed: 14235 Downloaded: 1872
Open Access
Review
Methods for extracellular vesicle isolation from cancer cells
Cells are known to release different types of vesicles such as small extracellular vesicles (sEVs) and large extracellular vesicles (LEVs). sEVs and LEVs play important roles in intercellular communication, pre-metastatic niche formation, and disease progression; both can be detected cell......
This article belongs to the Special Issue Application of Liquid Biopsy for Prognostic Status of Cancers and Drug Response
Cancer Drug Resist 2020;3:371-384.
Published on: 25 Apr 2020
Viewed: 913 Downloaded: 162
Open Access
Original Article
MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I...
Immunotherapy and immune checkpoint inhibitors (ICI) have changed cancer care for many patients; however, breast cancers have exhibited minimal response to single agent ICI therapy. There is a significant need to identify novel targets capable of increasing cancer cell immunogenicity and......
This article belongs to the Special Issue Promises and Pitfalls of Kinase Inhibitors as Therapeutics for Cancer Resistance
Cancer Drug Resist 2020;3:603-612.
Published on: 25 Apr 2020
Viewed: 519 Downloaded: 104
Articles
-
Open Access Letter to Editor
Platinum drug sensitivity and resistance in testicular germ cell tumors: two sides of the same coin
Pasquale Rescigno, ... Giovannella PalmieriCancer Drug Resist 2020;3:672-675.DOI: 10.20517/cdr.2020.24Available online: 16 Jun 2020 Viewed: 297 Downloaded: 63 -
Open Access Commentary
Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
Thales Paulo Batista, Graziela Zibetti Dal MolinCancer Drug Resist 2020;3:666-671.DOI: 10.20517/cdr.2020.27Available online: 10 Jul 2020 Viewed: 596 Downloaded: 76 -
Open Access Original ArticleReversal of doxorubicin resistance in lung cancer cells by neferine is explained by nuclear factor erythroid-derived 2-like 2 mediated lung resistance protein down regulation
Poornima Paramasivan, ... Viswanadha Vijaya PadmaCancer Drug Resist 2020;3:647-665.Available online: 17 Apr 2020 Viewed: 437 Downloaded: 85 -
Open Access Original ArticleQuantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel
Eiman Mukhtar, ... Paraskevi GiannakakouThis article belongs to the Special Issue Application of Liquid Biopsy for Prognostic Status of Cancers and Drug ResponseCancer Drug Resist 2020;3:636-646.Available online: 17 Apr 2020 Viewed: 649 Downloaded: 146 -
Open Access Original Article
Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma
Alicia Martínez-González, ... Pedro C. LaraThis article belongs to the Special Issue New Challenges in Overcoming Chemoresistance in GlioblastomaCancer Drug Resist 2020;3:623-635.DOI: 10.20517/cdr.2020.33Available online: 7 Aug 2020 Viewed: 245 Downloaded: 61 -
Open Access Original ArticleMicrofluidic chip enables single-cell measurement for multidrug resistance in triple-negative breast cancer cells
Karan Parekh, ... Paul Chi Hang LiThis article belongs to the Special Issue Application of Liquid Biopsy for Prognostic Status of Cancers and Drug ResponseCancer Drug Resist 2020;3:613-622.DOI: 10.20517/cdr.2019.77Available online: 11 Mar 2020 Viewed: 592 Downloaded: 130 -
Open Access Original ArticleMEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression
Derek A. Franklin, ... Justin M. BalkoThis article belongs to the Special Issue Promises and Pitfalls of Kinase Inhibitors as Therapeutics for Cancer ResistanceCancer Drug Resist 2020;3:603-612.Available online: 25 Apr 2020 Viewed: 519 Downloaded: 104 -
Open Access Original ArticleIdentification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cells
Linda T. Senbanjo, ... Meenakshi A. ChellaiahThis article belongs to the Special Issue Resistance in Endocrine Therapy of Prostate CancerCancer Drug Resist 2020;3:586-602.DOI: 10.20517/cdr.2020.21Available online: 21 Aug 2020 Viewed: 224 Downloaded: 49
-
Open Access ReviewHitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer
Maria Sendino, ... Jose Antonio RodríguezThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:139-163.DOI: 10.20517/cdr.2018.09Published on: 19 Sep 2018 Viewed: 28073 Downloaded: 1473 -
Open Access ReviewGlutamine metabolism in cancer therapy
Tra-Ly Nguyen, Raúl V. DuránThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:126-138.DOI: 10.20517/cdr.2018.08Published on: 19 Sep 2018 Viewed: 26023 Downloaded: 2057 -
Open Access ReviewMolecular bases of Sorcin-dependent resistance to chemotherapeutic agents
Ilaria Genovese, ... Gianni ColottiThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:164-180.DOI: 10.20517/cdr.2018.10Published on: 19 Sep 2018 Viewed: 22690 Downloaded: 1504 -
Open Access ReviewResistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
Heidi Schwarzenbach, Peter B. GahanThis article belongs to the Special Issue Epigenetic Basis of Cancer Drug ResistanceCancer Drug Resist 2019;2:271-296.Published on: 19 Jun 2019 Viewed: 20233 Downloaded: 922 -
Open Access ReviewDrug resistance and combating drug resistance in cancer
Xuan Wang, ... Xiaozhuo ChenThis article belongs to the Special Issue Drug Resistance Mechanisms in CancerCancer Drug Resist 2019;2:141-160.DOI: 10.20517/cdr.2019.10Published on: 19 Jun 2019 Viewed: 18609 Downloaded: 2263 -
Open Access ReviewSphingolipid metabolism and drug resistance in ovarian cancer
Kelly M. Kreitzburg, ... Karina J. YoonCancer Drug Resist 2018;1:181-197.DOI: 10.20517/cdr.2018.06Published on: 19 Sep 2018 Viewed: 17490 Downloaded: 1810 -
Open Access EditorialCancer drug resistance: a new perspective
Godefridus J. PetersCancer Drug Resist 2018;1:1-5.DOI: 10.20517/cdr.2018.03Published on: 19 Mar 2018 Viewed: 14235 Downloaded: 1872 -
Open Access ReviewHow to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
Adrian C. Jaramillo, ... Godefridus J. PetersCancer Drug Resist 2018;1:6-29.DOI: 10.20517/cdr.2018.02Published on: 19 Mar 2018 Viewed: 12010 Downloaded: 1342
-
Open Access Review
Drug resistance and combating drug resistance in cancer
Xuan Wang, ... Xiaozhuo ChenThis article belongs to the Special Issue Drug Resistance Mechanisms in CancerCancer Drug Resist 2019;2:141-160.DOI: 10.20517/cdr.2019.10Published on: 19 Jun 2019 Viewed: 18609 Downloaded: 2263 -
Open Access Review
Glutamine metabolism in cancer therapy
Tra-Ly Nguyen, Raúl V. DuránThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:126-138.DOI: 10.20517/cdr.2018.08Published on: 19 Sep 2018 Viewed: 26023 Downloaded: 2057 -
Open Access Editorial
Cancer drug resistance: a new perspective
Godefridus J. PetersCancer Drug Resist 2018;1:1-5.DOI: 10.20517/cdr.2018.03Published on: 19 Mar 2018 Viewed: 14235 Downloaded: 1872 -
Open Access Review
Sphingolipid metabolism and drug resistance in ovarian cancer
Kelly M. Kreitzburg, ... Karina J. YoonCancer Drug Resist 2018;1:181-197.DOI: 10.20517/cdr.2018.06Published on: 19 Sep 2018 Viewed: 17490 Downloaded: 1810 -
Open Access Review
Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents
Ilaria Genovese, ... Gianni ColottiThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:164-180.DOI: 10.20517/cdr.2018.10Published on: 19 Sep 2018 Viewed: 22690 Downloaded: 1504 -
Open Access Review
Hitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer
Maria Sendino, ... Jose Antonio RodríguezThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:139-163.DOI: 10.20517/cdr.2018.09Published on: 19 Sep 2018 Viewed: 28073 Downloaded: 1473 -
Open Access Review
How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
Adrian C. Jaramillo, ... Godefridus J. PetersCancer Drug Resist 2018;1:6-29.DOI: 10.20517/cdr.2018.02Published on: 19 Mar 2018 Viewed: 12010 Downloaded: 1342 -
Open Access ReviewDrug targets and resistance mechanisms in multiple myeloma
Janine Nass, Thomas EfferthCancer Drug Resist 2018;1:87-117.DOI: 10.20517/cdr.2018.04Published on: 19 Jun 2018 Viewed: 9029 Downloaded: 1294
-
Open Access Review
How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
Adrian C. Jaramillo, ... Godefridus J. PetersCancer Drug Resist 2018;1:6-29.DOI: 10.20517/cdr.2018.02Published on: 19 Mar 2018 Viewed: 12010 Downloaded: 1342 -
Open Access Review
Drug resistance and combating drug resistance in cancer
Xuan Wang, ... Xiaozhuo ChenThis article belongs to the Special Issue Drug Resistance Mechanisms in CancerCancer Drug Resist 2019;2:141-160.DOI: 10.20517/cdr.2019.10Published on: 19 Jun 2019 Viewed: 18609 Downloaded: 2263 -
Open Access Review
Drug targets and resistance mechanisms in multiple myeloma
Janine Nass, Thomas EfferthCancer Drug Resist 2018;1:87-117.DOI: 10.20517/cdr.2018.04Published on: 19 Jun 2018 Viewed: 9029 Downloaded: 1294 -
Open Access Editorial
Cancer drug resistance: a new perspective
Godefridus J. PetersCancer Drug Resist 2018;1:1-5.DOI: 10.20517/cdr.2018.03Published on: 19 Mar 2018 Viewed: 14235 Downloaded: 1872 -
Open Access ReviewResistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Nele Van Der Steen, ... Godefridus J. PetersThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:230-249.DOI: 10.20517/cdr.2018.13Published on: 19 Dec 2018 Viewed: 7409 Downloaded: 894 -
Open Access Original ArticleImproved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations
Anthony Dominijanni, William H. GmeinerCancer Drug Resist 2018;1:48-58.DOI: 10.20517/cdr.2018.01Published on: 19 Mar 2018 Viewed: 5242 Downloaded: 394 -
Open Access ReviewThe role of exosomal long non-coding RNAs in cancer drug resistance
Mireia Cruz De los Santos, ... George A. CalinThis article belongs to the Special Issue Non-coding RNAs in Response and Resistance to Therapy in CancerCancer Drug Resist 2019;2:1178-1192.DOI: 10.20517/cdr.2019.74Published on: 19 Dec 2019 Viewed: 2496 Downloaded: 656 -
Open Access ReviewEntrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs
William H. GmeinerThis article belongs to the Special Issue Targeting DNA Topoisomerases – Past and FutureCancer Drug Resist 2019;2:994-1001.DOI: 10.20517/cdr.2019.95Published on: 19 Dec 2019 Viewed: 702 Downloaded: 164
-
Open Access EditorialTargeted therapies in cancer: where are we going?
Elisa Giovannetti, Jose A. RodriguezThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:82-86.DOI: 10.20517/cdr.2018.05Published on: 19 Jun 2018 Viewed: 6526 Downloaded: 1114 -
Open Access OpinionLinking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses
Natalia J. Gurule, Lynn E. HeasleyThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:118-125.DOI: 10.20517/cdr.2018.12Published on: 19 Sep 2018 Viewed: 8950 Downloaded: 1068 -
Open Access Review
Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents
Ilaria Genovese, ... Gianni ColottiThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:164-180.DOI: 10.20517/cdr.2018.10Published on: 19 Sep 2018 Viewed: 22690 Downloaded: 1504 -
Open Access Review
Hitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer
Maria Sendino, ... Jose Antonio RodríguezThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:139-163.DOI: 10.20517/cdr.2018.09Published on: 19 Sep 2018 Viewed: 28073 Downloaded: 1473 -
Open Access Review
Glutamine metabolism in cancer therapy
Tra-Ly Nguyen, Raúl V. DuránThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:126-138.DOI: 10.20517/cdr.2018.08Published on: 19 Sep 2018 Viewed: 26023 Downloaded: 2057 -
Open Access Review
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Nele Van Der Steen, ... Godefridus J. PetersThis article belongs to the Special Issue Targeted Cancer TherapyCancer Drug Resist 2018;1:230-249.DOI: 10.20517/cdr.2018.13Published on: 19 Dec 2018 Viewed: 7409 Downloaded: 894 -
Open Access Meeting AbstractsMeeting Abstracts of the BACR conference: response and resistance in cancer therapy
This article belongs to the Special Issue Papers from the BACR Conference-Response and Resistance in Cancer TherapyCancer Drug Resist 2018;1:266-302.DOI: 10.20517/cdr.2018.18Published on: 19 Dec 2018 Viewed: 2601 Downloaded: 403 -
Open Access EditorialWhat really matters - response and resistance in cancer therapy
Tim R. Fenton, ... Martin MichaelisThis article belongs to the Special Issue Papers from the BACR Conference-Response and Resistance in Cancer TherapyCancer Drug Resist 2018;1:200-203.DOI: 10.20517/cdr.2018.19Published on: 19 Dec 2018 Viewed: 2186 Downloaded: 415
Editor-in-Chief
Journal Data Analysis
Special Issue eBook
Publisher
-
Cancer Drug Resistance is published by OAE Publishing Inc.
